v3.26.3
Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment - Footnotes (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2026
Sep. 27, 2026
Sep. 28, 2025
Sep. 27, 2026
Sep. 28, 2025
Segment Reporting [Line Items]          
Acquired in-process research and development expenses   $ 669 $ 1,390 $ 822 $ 1,401
Restructuring charges and certain acquisition-related costs   893   1,600  
Certain asset impairments [1]   0 260 4,325 577
Certain legal matters, net [2]   13 191 1,047 755
Net gain from the sale of investment in ViiV [3]   0 0 1,870 0
Restructuring charges         1,000
3SBio [Member] | In-Licensing Agreement Option [Member]          
Segment Reporting [Line Items]          
Acquired in-process research and development expenses     1,350   1,350
Innovent [Member] | Collaborative Arrangement [Member]          
Segment Reporting [Line Items]          
Upfront payment to collaborators $ 650 650   650  
ViiV [Member]          
Segment Reporting [Line Items]          
Dividend income   (58) (72) (239) (184)
Biopharma [Member]          
Segment Reporting [Line Items]          
Acquired in-process research and development expenses   19 40 172 51
Biopharma [Member] | ViiV [Member]          
Segment Reporting [Line Items]          
Dividend income   $ (58) $ (72) $ (239) $ (184)
[1] The amount for the first nine months of 2026 represents intangible asset impairment charges associated with our Biopharma segment, composed of: (i) $3.8 billion in impairments of IPR&D assets associated with a Phase 3 study for sigvotatug vedotin for the second line treatment of metastatic non-squamous NSCLC, reflecting unfavorable clinical trial results, and (ii) $525 million for Oxbryta (voxelotor) developed technology rights, after engaging with the FDA in July 2026 to discuss their assessment of data and analyses, and it was determined there was no viable pathway to return Oxbryta to the market in the U.S. The amounts for the third quarter and first nine months of 2025 included an intangible asset impairment charge associated with our Biopharma segment of $260 million related to IPR&D associated with a Phase 3 study for inclacumab for the treatment of SCD, which reflected unfavorable clinical trial results. The amount for the first nine months of 2025 also included an intangible asset impairment charge associated with our Biopharma segment of $210 million for a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner.
[2] The amount for the first nine months of 2026 primarily includes certain product liability and other legal expenses. The amount for the third quarter of 2025 primarily included certain product liability expenses. The amount for the first nine months of 2025 primarily included certain product liability and other legal expenses.
[3] See Note 2C.